Ruxolitinib Adverse Event Data and Strategies for Managing Side Effects
April 7th 2022Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
Watch
Introduction: A 58-Year-Old Man With Moderate Steroid-Refractory cGVHD and Risk Factors for cGVHD
April 7th 2022Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.
Watch